| Identification | More | [Name]
Pazufloxacin | [CAS]
127045-41-4 | [Synonyms]
(3S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-2,3-DIHYDRO-3-METHYL-7-OXO-7H-PYRIDO[1,2,3-DE]-1,4-BENZOXAZINE-6-CARBOXYLIC ACID
ALKALYL
PAZUFLOXAXIN
T-3761
(s)-yclopropyl)-9-fluoro-3-methyl-7-oxo
Pazufloxacinmyesylate
Pazufloxaxin mesilate
PAZUFLOXACIN 98+%
(S)-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
Pazufloxacin318.3
Pazufloxacine
PAZUFLOXACIN (PREPARATION FOR PAZUFLOXACIN MESILATE)
PAZUFLOXACIN(ALKALYL)
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-(9CI)
(-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (3S)-(9CI)
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-
(S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-3-METHYL-7-OXO-3,7-DIHYDRO-2H-[1,4]OXAZINO[2,3,4-IJ]QUINOLINE-6-CARBOXYLIC ACID
7H-Pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 2,3-dihydro-10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-, (S)- | [EINECS(EC#)]
635-036-1 | [Molecular Formula]
C16H15FN2O4 | [MDL Number]
MFCD00865012 | [Molecular Weight]
318.3 | [MOL File]
127045-41-4.mol |
| Chemical Properties | Back Directory | [Melting point ]
269-271°C | [alpha ]
D25 -88.0° (c = 0.5 in 0.05N aq NaOH) | [Boiling point ]
531.5±50.0 °C(Predicted) | [density ]
1.56 | [storage temp. ]
2-8°C | [solubility ]
Aqueous Base (Slightly, Sonicated), DMSO (Slightly, Heated), Methanol (Slightly) | [form ]
neat | [pka]
5.05±0.40(Predicted) | [color ]
Off-White to Pale Yellow | [CAS DataBase Reference]
127045-41-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,C,F | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R34:Causes burns.
R11:Highly Flammable. | [Safety Statements ]
S36/37:Wear suitable protective clothing and gloves .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S16:Keep away from sources of ignition-No smoking . | [WGK Germany ]
3 | [RTECS ]
UU8815300 | [Toxicity]
LD50 i.v. in male mice: >500 mg/kg (Todo) |
| Raw materials And Preparation Products | Back Directory | [Raw materials]
Ethyl acetate-->Trifluoroacetic acid-->Sodium sulfite-->Sodium azide-->Paraformaldehyde-->N,N-Dimethylformamide dimethyl acetal-->Dimethyl sulfide-->Methanesulfonic acid-->1,1'-Carbonyldiimidazole-->5-(Acetamido)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide-->Diphenyldiazomethane-->Ethyl 2,3,4,5-tetrafluorobenzoate-->Di-tert-Butyl malonate |
| Questions And Answer | Back Directory | [Description]
Pazufloxacin is a fluoroquinolone with a 1-aminocyclopropyl substituent at C10 position. The presence of aminoacyl group at C-10 is a unique feature of the molecule imparting potent broad spectrum activity against gram-positive and gram-negative bacteria. This activity is based on the inhibition of bacterial DNA gyrase.
Pazufloxacin is used as an injectable antibiotic with bacterial effect against cephalosporin-resistant, carbapenem-resistance, and aminoglycoside resistant strains of bacteria. The adverse effects of pazufloxacin, such as drug-induced convulsion and hypotension are less than those of other conventional injectable fluoroquinolones.
| [References]
[1] A. Vora, Pazufloxacin, tracked from www.japi.org on 16.07.2017
[2] Jeffrey K. Aronson, Meyler’s Side Effects of Antimicrobial Drugs, 2009
[3] Satoshi Watabe, Yoshiaki Yokoyama, Kazuyuki Nakazawa, Kimikazu Shinozaki, Rika Hiraoka, Kei Takeshita and Yukio Suzuki, Simultaneous measurement of pazufloxacin, ciprofloxacin, and levofloxacin in human serum by high-performance liquid chromatography with fluorescence detection, Journal of Chromatography B, 2010, vol. 878, 1555-1561
|
| Hazard Information | Back Directory | [Originator]
Toyama (Japan) | [Uses]
antibactierial | [Uses]
Pazufloxacin is a potential antimicrobial and/or antiviral agent. | [Definition]
ChEBI: LSM-5745 is a member of quinolines. | [Brand name]
Pasil, Pazucross | [Pharmaceutical Applications]
A tricyclic fluoroquinolone, formulated as mesylate and hydrochloride salts for oral or parenteral use or as a methane sulfonate (eye ointment).
It displays good activity in vitro against methicillin
susceptible Staph. aureus (MIC 0.2 mg/L), but is inactive against Str. pyogenes, Str. pneumoniae (MIC ≥4 mg/L) and enterococci. L. pneumophila is inhibited by 0.03 mg/L. Activity against Enterobacteriaceae, fastidious Gram-negative bacilli, Ps. aeruginosa and Acinetobacter spp. is similar to that of ofloxacin. It is weakly active against Sten. maltophilia and Burkholderia cepacia (MIC c. 2 mg/L). Against M. tuberculosis, MICs range from 0.8 to 4 mg/L. It is inactive against anaerobes.
After oral doses of 100 or 400 mg, peak plasma concentrations range from 0.94 mg/L (100 mg) to 4.5 mg/L (400 mg) after <1 h. The apparent elimination half-life is around 2 h. Most of the administered dose is eliminated in urine, about 70% within 24 h. Four metabolites have been reported. In elderly patients, according to the renal function, the peak plasma concentration may be elevated (up to 5.6 mg/L) and significantly delayed (2–6 h). The plasma protein binding ranges from 17% to 28%. | [storage]
Store at -20°C |
|
|